📰 Risk Evaluation News
Page 32 - Risk Evaluation News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Risk Evaluation. Real-time updates on events, politics, business and more.
May 9, 2023
As the COVID-19 pandemic continues across the United States, states, payers, and providers are looking for ways to expand access to telehealth services. Telehealth is an essential tool...
May 8, 2023
05.08.23 (PRESS RELEASE) — Today, abortion providers in Virginia, Montana, and Kansas filed a federal lawsuit against the Food and Drug Administration
May 7, 2023
Lack of drought conditions in most of Minnesota is expected to alleviate air quality issues.
May 5, 2023
All new drugs that have never before been sold in Canada in any form, as well as all opioids, require RMPs to help safeguard the public.
May 4, 2023
Generated U.S. net product revenues of $18.4 million for SYFOVRE™ and $20.4 million for EMPAVELI® SYFOVRE launched in the U.S. as the first and only treatment for geographic atrophy ... | May 4, 2023
May 4, 2023
Health Canada continues to monitor newly approved drugs to determine if the benefits identified in the pre-market trials hold up to further scrutiny. Canadians need better access to that information.
May 3, 2023
The Pharmaceutical Research and Manufacturers of America has waded into the mifepristone controversy by filing an amicus brief – along with other industry stakeholders – asking for a reversal of a lower court decision in Alliance for Hippocratic Medicine v. the U.S. Food and Drug Administration. More than 250 congressional Democrats have also filed a brief urging an appeals
May 2, 2023
Extended-release sodium oxybate (Lumryz) is taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy.